https://www.selleckchem.com/products/ms-275.html
7%) at day 21 ( = 0.02). Clinical parameters remained stable and leptomeningeal enhancements remained unchanged. Clinical outcome and biomarkers of inflammation were not dramatically modified after IT injection of rituximab, probably due to its limited efficiency in CSF. Drug issues for future studies are discussed. Clinical outcome and biomarkers of inflammation were not dramatically modified after IT injection of rituximab, probably due to its limited efficiency in CSF. Drug issues for future studies are discussed. Regular physical act
Like
Comment
Share
